HX 531 - ≥98%(HPLC), high purity , CAS No.188844-34-0, Antagonist of Retinoid X receptor-α

Item Number
H287547
Grouped product items
SKUSizeAvailabilityPrice Qty
H287547-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$147.90
H287547-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$666.90

Potent RXR antagonist

Basic Description

SynonymsCS-0029089 | DTXSID801107570 | HY-108521 | BDBM50218464 | 4-(7,8,9,10-Tetrahydro-5,7,7,10,10-pentamethyl-2-nitro-5H-benzo[b]naphtho[2,3-e][1,4]diazepin-12-yl)benzoic acid | CID 11755040 | (Z)-4-(5,7,7,10,10-pentamethyl-2-nitro-7,8,9,10-tetrahydro-5H-benzo
Specifications & PurityMoligand™, ≥98%(HPLC)
Biochemical and Physiological MechanismsPotent RXR antagonist (IC50= 18 nM). Promotes white and brown pre-adipocyte differentiation into white adipocytes. Also inhibitsbexarotene-induced brown adipogenic reprogramming of myoblasts.
Storage TempStore at 2-8°C
Shipped InWet ice
GradeMoligand™
Action TypeANTAGONIST
Mechanism of actionAntagonist of Retinoid X receptor-α

Associated Targets(Human)

RXRB Tclin Retinoic acid receptor RXR-beta (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
RXRA Tclin Retinoic acid receptor RXR-alpha (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
RXRG Tclin Retinoid X receptor gamma (646 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RXRA Tclin Retinoid X receptor alpha (3637 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name 4-(5,7,7,10,10-pentamethyl-2-nitro-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid
INCHI InChI=1S/C29H29N3O4/c1-28(2)12-13-29(3,4)22-16-25-20(15-21(22)28)26(17-6-8-18(9-7-17)27(33)34)30-23-14-19(32(35)36)10-11-24(23)31(25)5/h6-11,14-16H,12-13H2,1-5H3,(H,33,34)
InChi Key SXKPGYKPQPYJER-UHFFFAOYSA-N
Canonical SMILES CC1(CCC(C2=C1C=C3C(=C2)N(C4=C(C=C(C=C4)[N+](=O)[O-])N=C3C5=CC=C(C=C5)C(=O)O)C)(C)C)C
Isomeric SMILES CC1(CCC(C2=C1C=C3C(=C2)N(C4=C(C=C(C=C4)[N+](=O)[O-])N=C3C5=CC=C(C=C5)C(=O)O)C)(C)C)C
PubChem CID 11755040
Molecular Weight 483.56

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Chemical and Physical Properties

SolubilitySolvent:DMSO, Max Conc. mg/mL: 9.67, Max Conc. mM: 20

Safety and Hazards(GHS)

RIDADR NONHforallmodesoftransport

Related Documents

References

1. Ebisawa M, Umemiya H, Ohta K, Fukasawa H, Kawachi E, Christoffel G, Gronemeyer H, Tsuji M, Hashimoto Y, Shudo K et al..  (1999)  Retinoid X receptor-antagonistic diazepinylbenzoic acids..  Chem Pharm Bull,  47  (12): (1778-86).  [PMID:10748721] [10.1021/op500134e]
2. Sakaki J, Konishi K, Kishida M, Gunji H, Kanazawa T, Uchiyama H, Fukaya H, Mitani H, Kimura M.  (2007)  Synthesis and structure-activity relationship of RXR antagonists based on the diazepinylbenzoic acid structure..  Bioorg Med Chem Lett,  17  (17): (4808-11).  [PMID:17651969] [10.1021/op500134e]

Solution Calculators